Evolus reports Q2 non-GAAP operating income $1.1M vs. ($8.0M) last year

Reports Q2 revenue $66.9M, consensus $65.8M. “We are thrilled to have achieved quarterly profitability1 for the first time, driven by record revenue, demonstrating our continued strong execution and unwavering commitment to building a leadership position in the performance beauty industry,” said David Moatazedi, President and Chief Executive Officer. “With record quarterly revenue and all-time highs across key performance indicators, we are raising our full-year 2024 net revenue guidance to between $260 million and $270 million, equating to growth of over 30% for our fifth consecutive year since commercialization. As we advance toward achieving our 2028 revenue goal of at least $700 million, we are pleased with the continued strength of Jeuveau(R), the ongoing expansion of our global footprint into the largest markets internationally, and the progress we’ve made in expanding our portfolio with the recent submission of the PMA to the FDA for our first two Evolysse(TM) dermal filler products. We anticipate approval and launch of these fillers in the second half of 2025, along with the planned approval of the Estyme(R) dermal filler products in Europe in late 2024 and launch in 2025.”